Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Clinical Genetics · Mitochondrial Myopathy, Lactic Acidosis, and Sideroblastic Anemia

Biology, Subtypes, and Look-Alikes: Why the Details Matter

At a Glance

MLASA is an inherited disorder of mitochondrial energy production caused by PUS1 or YARS2 variants. MLASA1 and MLASA2 can cause different combinations of muscle weakness, lactic acidosis, and sideroblastic anemia, so genetic testing helps distinguish them from ALAS2-related anemia, MELAS, and Pearson syndrome.

While MLASA is a single diagnosis, it is actually a group of conditions caused by different genetic variants. Understanding whether you have MLASA1 or MLASA2—and how they differ from other similar-looking conditions—is key to managing your care.

Genetics and Inheritance

Both MLASA1 and MLASA2 are autosomal recessive, meaning a person must inherit one changed gene from each parent to develop the condition [1][2]. If both parents are carriers, there is a 25% recurrence risk with each pregnancy. A genetic counselor can discuss carrier testing for relatives and reproductive options.

MLASA1 (The PUS1 Gene)

This form is caused by changes in the PUS1 gene. It is exceptionally rare, with very few documented cases worldwide [3].

  • The Variant: The PUS1 gene is responsible for “pseudouridylation”—a process that modifies tRNA (the “delivery trucks” for protein building blocks) so they can function correctly [4].
  • Systemic Nature: Because this gene is active in many parts of the body, MLASA1 can sometimes involve more than just muscles and blood. Some patients may experience developmental delays, growth issues, or problems with the liver or heart [1][5].

MLASA2 (The YARS2 Gene)

This form is caused by changes in the YARS2 gene and is the most commonly reported type of MLASA [6].

  • The Variant: The YARS2 gene provides instructions for “charging” a specific tRNA (the tyrosine tRNA). If this function is impaired, mitochondrial protein synthesis and respiratory-chain function are reduced [2][7].
  • Variability: MLASA2 can look very different from person to person. Some may have the full triad (myopathy, lactic acidosis, and anemia), while others might only have muscle weakness or only anemia [2][8].

Why the “Power Plants” Fail

To understand MLASA, imagine your cells are factories. Mitochondria are the power plants that keep the lights on.

  1. The Delivery Trucks (tRNA): In MLASA, the “delivery trucks” (tRNAs) that carry building blocks for proteins are impaired (MLASA1) or undercharged (MLASA2) [4][7].
  2. The Assembly Line Slows: Because the trucks can’t deliver their cargo efficiently, the factory can’t build the proteins needed for the respiratory chain—the specific machinery that generates energy (ATP) [9].
  3. The Resulting Crisis:
    • In Muscles: Without enough energy, muscles tire instantly, leading to myopathy [8].
    • In Blood Precursors: Nucleated red blood cell precursors require a massive amount of energy to make hemoglobin. When the energy fails, iron can’t be used and instead piles up in the cell, creating “ring sideroblasts” [4][10].

Differentiating MLASA from “Look-Alikes”

Because MLASA shares symptoms with other conditions, doctors use specific clues to tell them apart.

MLASA vs. ALAS2-Related Anemia

ALAS2 is a common cause of congenital sideroblastic anemia. Unlike MLASA, it is X-linked, meaning it primarily affects males, though females can be symptomatic [11]. Crucially, patients with ALAS2 mutations typically do not have the muscle weakness or lactic acidosis that define MLASA [12]. Note that sideroblastic anemia can also be acquired later in life due to medications, toxins, or marrow disorders.

MLASA vs. Other Mitochondrial Disorders

  • MELAS: While MELAS also features lactic acidosis and myopathy, its hallmark is “stroke-like episodes” and brain involvement (encephalopathy), which are not typical for MLASA [13][14].
  • Pearson Syndrome: This usually starts in early infancy and involves profound problems with the pancreas and growth [15]. It is usually assessed with appropriate large-scale mtDNA deletion testing, rather than a specific nuclear gene mutation like MLASA [16][15].
Feature (General Patterns) MLASA ALAS2 (XLSA) Pearson Syndrome
Primary Symptoms Anemia + Muscle Weakness Anemia Anemia + Pancreas issues
Genetics Autosomal Recessive X-Linked Sporadic DNA Deletion
Lactic Acidosis Common Rare Common

Identifying the specific genetic cause requires a clinical geneticist, as it dictates how your medical team will monitor your heart, lungs, and blood over time [6][8].

Common questions in this guide

What are MLASA1 and MLASA2?
MLASA1 is the form linked to changes in the PUS1 gene, while MLASA2 is linked to changes in the YARS2 gene. Both can impair mitochondrial energy production, but the combination and severity of muscle symptoms, lactic acidosis, and anemia can vary widely.
How is MLASA inherited?
MLASA1 and MLASA2 are autosomal recessive conditions, so a person inherits a disease-causing gene change from each parent. When both parents are carriers, each pregnancy has a 25% chance of being affected, and genetic counseling can discuss family testing and reproductive options.
Why can MLASA cause both muscle weakness and sideroblastic anemia?
PUS1 or YARS2 changes can disrupt the cell machinery that helps mitochondria make proteins and energy. Muscle cells may then tire easily, while developing red blood cells may be unable to use iron properly, causing iron buildup called ring sideroblasts and leading to sideroblastic anemia.
How is MLASA different from ALAS2-related sideroblastic anemia?
ALAS2-related congenital sideroblastic anemia is usually X-linked and often affects males, whereas MLASA is autosomal recessive. People with ALAS2-related anemia typically do not have the muscle weakness or lactic acidosis that commonly point toward MLASA, although sideroblastic anemia can also be acquired from medications, toxins, or marrow disorders.
How can doctors tell MLASA apart from MELAS and Pearson syndrome?
MELAS more typically includes stroke-like episodes and brain involvement, while Pearson syndrome usually begins in infancy with severe pancreatic and growth problems. Finding disease-causing variants in both copies of PUS1 or YARS2 supports MLASA, and testing for large-scale mitochondrial DNA deletions may help evaluate for Pearson syndrome.

Get notified when new evidence is published on Mitochondrial myopathy and sideroblastic anemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Respiratory complex I deficiency caused by a novel multi-exonic PUS1 deletion.

    Yuan JH, Higuchi Y, Ando M, et al.

    Journal of human genetics 2026; (71(5)):275-282 doi:10.1038/s10038-025-01437-8.

    PMID: 41361485
  2. 2

    The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2.

    Riley LG, Heeney MM, Rudinger-Thirion J, et al.

    Haematologica 2018; (103(12)):2008-2015 doi:10.3324/haematol.2017.182659.

    PMID: 30026338
  3. 3

    Myopathy, lactic acidosis and sideroblastic anemia 1 (MLASA1): A 25-year follow-up.

    Woods J, Cederbaum S

    Molecular genetics and metabolism reports 2019; (21()):100517 doi:10.1016/j.ymgmr.2019.100517.

    PMID: 31641589
  4. 4

    Mitochondrial tRNA pseudouridylation governs erythropoiesis.

    Wang B, Shi D, Yang S, et al.

    Blood 2024; (144(6)):657-671 doi:10.1182/blood.2023022004.

    PMID: 38635773
  5. 5

    A Novel PUS1 Mutation in 2 Siblings with MLASA Syndrome: A Review of the Literature.

    Oncul U, Unal-Ince E, Kuloglu Z, et al.

    Journal of pediatric hematology/oncology 2021; (43(4)):e592-e595 doi:10.1097/MPH.0000000000001806.

    PMID: 32287105
  6. 6

    Correlation of MLASA2 Clinical Phenotype and Survival with Mt-TyrRS Protein Damage: Linking Systematic Review, Meta-Analysis and 3D Hotspot Mapping.

    Villafan-Bernal JR, Martínez-Hernández A, García-Ortiz H, et al.

    Current issues in molecular biology 2026; (48(1)) doi:10.3390/cimb48010095.

    PMID: 41614925
  7. 7

    Two Novel Variants in YARS2 Gene Are Responsible for an Extended MLASA Phenotype with Pancreatic Insufficiency.

    Carreño-Gago L, Juárez-Flores DL, Grau JM, et al.

    Journal of clinical medicine 2021; (10(16)) doi:10.3390/jcm10163471.

    PMID: 34441767
  8. 8

    Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy.

    Sommerville EW, Ng YS, Alston CL, et al.

    JAMA neurology 2017; (74(6)):686-694 doi:10.1001/jamaneurol.2016.4357.

    PMID: 28395030
  9. 9

    Pseudouridine synthase 1 deficient mice, a model for Mitochondrial Myopathy with Sideroblastic Anemia, exhibit muscle morphology and physiology alterations.

    Mangum JE, Hardee JP, Fix DK, et al.

    Scientific reports 2016; (6()):26202 doi:10.1038/srep26202.

    PMID: 27197761
  10. 10

    Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia.

    Fujiwara T, Harigae H

    Free radical biology & medicine 2019; (133()):179-185 doi:10.1016/j.freeradbiomed.2018.08.008.

    PMID: 30098397
  11. 11

    Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.

    Cazzola M, Malcovati L

    Hematology. American Society of Hematology. Education Program 2015; (2015()):19-25 doi:10.1182/asheducation-2015.1.19.

    PMID: 26637696
  12. 12

    Clinical and molecular study in a long-surviving patient with MLASA syndrome due to novel PUS1 mutations.

    Cao M, Donà M, Valentino ML, et al.

    Neurogenetics 2016; (17(1)):65-70 doi:10.1007/s10048-015-0465-x.

    PMID: 26556812
  13. 13

    When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis?

    Lorenzoni PJ, Werneck LC, Kay CS, et al.

    Arquivos de neuro-psiquiatria 2015; (73(11)):959-67.

    PMID: 26517220
  14. 14

    Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements.

    Mancuso M, Bellusci M, Carelli V, et al.

    European journal of neurology 2026; (33(4)):e70588 doi:10.1111/ene.70588.

    PMID: 41999163
  15. 15

    Pearson syndrome: a multisystem mitochondrial disease with bone marrow failure.

    Yoshimi A, Ishikawa K, Niemeyer C, Grünert SC

    Orphanet journal of rare diseases 2022; (17(1)):379 doi:10.1186/s13023-022-02538-9.

    PMID: 36253820
  16. 16

    Sideroblastic anemia associated with multisystem mitochondrial disorders.

    Tesarova M, Vondrackova A, Stufkova H, et al.

    Pediatric blood & cancer 2019; (66(4)):e27591 doi:10.1002/pbc.27591.

    PMID: 30588737

This page is for informational purposes only and does not constitute medical advice. A clinical geneticist and your hematology or neuromuscular team should interpret genetic tests, lactate results, and anemia findings for your specific situation.